RT Book, Section
A1 Euhus, David
A2 Morita, Shane Y.
A2 Balch, Charles M.
A2 Klimberg, V. Suzanne
A2 Pawlik, Timothy M.
A2 Posner, Mitchell C.
A2 Tanabe, Kenneth K.
SR Print(0)
ID 1145759910
T1 Genetic and Familial Syndromes
T2 Textbook of Complex General Surgical Oncology
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071793315
LK hemonc.mhmedical.com/content.aspx?aid=1145759910
RD 2024/04/24
AB Genetic  predisposition  accounts  for  only  a  fraction  of  breast  cancers,  but  genetic  testing,  in  the  appropriate  context,  is  the  most  powerful  tool  available  for  quantitative  risk  stratification.  The  information  provided  by  genetic  testing  contributes  directly  to  risk  management  decisions  and,  frequently,  to  decisions  about  cancer  treatment.  BRCA1  and  BRCA2  are  still  responsible  for  the  majority  of  hereditary  breast  cancer  cases,  but  the  list  of  rare  genes  is  increasing  rapidly.  The  commercialization  of  massive  parallel  sequencing  tests  (i.e.,  next  generation  sequencing)  has  revolutionized  genetic  testing.  Panel  testing  is  becoming  more  common  and  patients  are  presenting  more  frequently  with  rare  mutations  in  genes  like  CHEK2,  PALB2,  and  ATM.